<span item_type="fundamental" item_id="0861e3d06faf0cb24a7baf024f24e739" counter_id="ST/US/INKT" env="prod"></span><span item_type="announcement" item_id="591495274061242241" env="prod"></span><p>EPS: As of FY2025 Q3, the actual value is USD -0.65, beating the estimate of USD -0.855.</p><p></p><h3>Cash Position</h3><p>MiNK Therapeutics ended Q3 2025 with approximately $14.3 million in cash and cash equivalents. The company raised an additional $1.2 million through equity sales, providing an expected cash runway through 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840229/000119312525311229/inkt-ex99_1.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1840229/000119312525311229/inkt-ex99_2.htm"></span></p><h3>Net Loss</h3><p>The net loss for Q3 2025 was $2.9 million, or $0.65 per share, compared to a net loss of $1.8 million, or $0.46 per share, for Q3 2024. For the nine months ended September 30, 2025, the net loss was $9.9 million, or $2.39 per share, compared to $8.3 million, or $2.24 per share, for the same period in 2024. These results reflect ongoing activity supporting the agent-797 programs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840229/000119312525311229/inkt-ex99_1.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1840229/000119312525311229/inkt-ex99_2.htm"></span></p><h3>Outlook / Guidance</h3><p>MiNK Therapeutics plans to initiate a Phase 1 GvHD study supported by NIH and philanthropy in Q1 2026. Early data from a randomized Phase 2 trial in severe pulmonary inflammatory disease is expected in 2026, along with clinical and translational updates from agenT-797 oncology and inflammatory cohorts. The company aims to continue progress on strategic partnerships and manufacturing optimization to support multi-program clinical execution throughout 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840229/000119312525311229/inkt-ex99_1.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1840229/000119312525311229/inkt-ex99_2.htm"></span></p>

MiNK Therapeutics | 8-K: FY2025 Q3 EPS Beats Estimate at USD -0.65